Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Date:3/26/2009

CHENGDU, China, March 26 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Board of Directors declared an annual cash dividend of $0.10 per common share that will be paid quarterly. Subject to approval by a majority of the Company's Series A Preferred Shareholders, the initial dividend of $.025 will be paid to common shareholders of record on April 30, 2009, with the actual distribution occurring on or about June 10, 2009. Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "Our dividend payment is in line with our desire to balance the cash required to operate and grow our business with that of providing and enhancing returns to our shareholders. We have carefully reviewed our current financial position, which includes cash and equivalents of approximately $12.7 million on December 31, 2008, in addition to our projected cash flow from operations, and are confident that Tianyin has sufficient resources to cover our operational and capital expenditures for the foreseeable future. We are committed to act in the best interest of our shareholders and will continue to make significant progress in growing our business."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel:   +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web:  http://www.hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
2. Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
4. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
9. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
10. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
(Date:4/26/2017)... ST. LOUIS (PRWEB) , ... April 26, 2017 ... ... is designed specifically to improve the profitability of ready-to-drink, high-protein beverages by helping ... an economic alternative to dairy proteins, providing direct cost savings as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: